interferon-alpha A-D

01/01/1990 - "A 20-day course of AZT + rHuIFN-alpha A/D started 4 h after virus exposure was protective against RLV viremia and disease. "
01/01/1990 - "This study was undertaken to calculate the in vivo drug interactions between recombinant human interferon-alpha A/D (rHuIFN-alpha A/D) and 3'-azido-3'-deoxythymidine (AZT) in a quantitative model for retroviral viremia. "

12/01/1993 - "In the murine tumor model, administration of rHuIFN-alpha A/D at 4 hours after light onset and rMuIFN-gamma at 16 hours after light onset may produce maximum antitumor activity."
01/01/1990 - "Administration of rHuIFN-alpha A/D and rMuIFN-gamma as single agents to tumor-bearing mice resulted in a dose-related antitumor effect in each of the six models studied. "
05/01/1988 - "Effect of recombinant human interferon-alpha A/D on in vivo murine tumor cell growth."
09/15/1987 - "Thus, injection of mice with rIL-2 and rHuIFN-alpha A/D results in the induction of an NK-cell-like population in the liver with enhanced cytotoxic activity that correlates with the observed anti-tumor activity in vivo in this murine model. "
08/01/1987 - "[Effects of recombinant human interferon-alpha A/D on the growth of experimental tumors in mice]."

10/01/1988 - "The effects of recombinant human leucocyte interferon alpha A/D on experimental myocarditis due to coxsackie virus B3 were investigated. "
06/01/1988 - "Thus, interferon alpha-A/D, when given before and simultaneously with virus, effectively inhibited replication of myocardial virus and reduced the inflammatory response and myocardial damage in an experimental model of viral myocarditis."
10/01/1988 - "Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D."
07/01/1995 - "Synergistic effects of tacrolimus and human interferon-alpha A/D in murine viral myocarditis."
09/01/1991 - "We investigated the effects of OK432, recombinant human interferon alpha A/D (rIFN alpha A/D) and a combination of these drugs on murine acute myocarditis due to encephalomyocarditis virus. "

01/01/1986 - "Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon alpha A/D."
01/01/1986 - "The effects of pure recombinant human interferon alpha A/D (IFN alpha A/D) on natural killer (NK) activity and the experimental lung metastasis of B16-F10 melanoma were studied. "
05/01/1994 - "The antitumor efficacy of recombinant murine interleukin-1 alpha (rMuIL-1 alpha) was evaluated either alone or in combination with recombinant human hybrid interferon alpha A/D (IFN-alpha A/D) against the murine B16 F10 malignant melanoma. "
02/15/1986 - "The in vitro antiproliferative effects of recombinant interferons (IFNs) alpha and gamma against the murine reticulum-cell sarcoma M5076 and the malignant melanoma B16 F10 were evaluated using the human hybrid IFN-alpha A/D (rHuIFN-alpha A/D), which is active on murine cells, and recombinant murine IFN gamma (rMuIFN-gamma). "
10/01/1985 - "Human recombinant interferon alpha A/D (alpha A/D) was examined for its antitumor activity in several mouse tumor models using metastatic tumors, such as B16 melanoma F1, BL6 and F10, UV2237m fibrosarcoma, and K1735m melanoma. "

08/01/1988 - "Two murine models, C3H 38C13 B-cell lymphoma and AKR SL2 T-cell lymphoma were used to determine the efficacy of three different interferon preparations, recombinant human hybrid interferon-alpha A/D, recombinant murine interferon (rMIFN)-gamma, and natural MIFN-alpha/beta (greater than or equal to 85% beta), alone and in combination with tumor specific and nonspecific monoclonal antibody therapy. "